Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Oct;81(3):542–548. doi: 10.1038/sj.bjc.6690728

Regular use of analgesics is a risk factor for renal cell carcinoma

M Gago-Dominguez 1, J-M Yuan 1, J E Castelao 1, R K Ross 1, M C Yu 1
PMCID: PMC2362920  PMID: 10507783

Abstract

Phenacetin-based analgesics have been linked to the development of renal pelvis cancer and renal cell carcinoma (RCC). The relationship between non-phenacetin types of analgesics and kidney cancer is less clear, although laboratory evidence suggests that these drugs possess carcinogenic potential. A population-based case–control study involving 1204 non-Asian RCC patients aged 25–74 and an equal number of sex-, age- and race-matched neighbourhood controls was conducted in Los Angeles, California, to investigate the relationship between sustained use of analgesics and risk of RCC according to major formulation categories. Detailed information on medical and medication histories, and other lifestyle factors was collected through in-person interviews. Regular use of analgesics was a significant risk factor for RCC in both men and women (odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.4–1.9 for both sexes combined). Risks were elevated across all four major classes of analgesics (aspirin, non-steroidal anti-inflammatory agents other than aspirin, acetaminophen and phenacetin). Within each class of analgesics, there was statistically significant increasing risk with increasing level of exposure. Although there was some minor variability by major class of formulation, in general individuals in the highest exposure categories exhibited approximately 2.5-fold increase in risk relative to non- or irregular users of analgesics. Subjects who took one regular-strength (i.e. 325 mg) aspirin a day or less for cardiovascular disease prevention were not at an increased risk of RCC (OR = 0.9, 95% CI = 0.6–1.4). © 1999 Cancer Research Campaign

Keywords: renal cell cancer, analgesics, NSAID, aspirin, acetaminophen, phenacetin

Full Text

The Full Text of this article is available as a PDF (83.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. H., Howie A. J., Michael J., McConkey B., Bacon P. A., Adu D. Non-steroidal anti-inflammatory drugs and renal failure. Lancet. 1986 Jan 11;1(8472):57–60. doi: 10.1016/s0140-6736(86)90714-2. [DOI] [PubMed] [Google Scholar]
  2. Armstrong B., Garrod A., Doll R. A retrospective study of renal cancer with special reference to coffee and animal protein consumption. Br J Cancer. 1976 Feb;33(2):127–136. doi: 10.1038/bjc.1976.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Asal N. R., Geyer J. R., Risser D. R., Lee E. T., Kadamani S., Cherng N. Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. Cancer Detect Prev. 1988;13(3-4):263–279. [PubMed] [Google Scholar]
  4. BRODIE B. B., AXELROD J. The fate of acetophenetidin in man and methods for the estimation of acetophenetidin and its metabolites in biological material. J Pharmacol Exp Ther. 1949 Sep;97(1):58–67. [PubMed] [Google Scholar]
  5. Bengtsson U., Angervall L., Ekman H., Lehmann L. Transitional cell tumors of the renal pelvis in analgesic abusers. Scand J Urol Nephrol. 1968;2(3):145–150. doi: 10.3109/00365596809135358. [DOI] [PubMed] [Google Scholar]
  6. Burrell J. H., Yong J. L., Macdonald G. J. Analgesic nephropathy in Fischer 344 rats: comparative effects of chronic treatment with either aspirin or paracetamol. Pathology. 1991 Apr;23(2):107–114. doi: 10.3109/00313029109060807. [DOI] [PubMed] [Google Scholar]
  7. Derby L. E., Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 1996 Jul;7(4):358–362. doi: 10.1097/00001648-199607000-00004. [DOI] [PubMed] [Google Scholar]
  8. Devesa S. S., Silverman D. T., McLaughlin J. K., Brown C. C., Connelly R. R., Fraumeni J. F., Jr Comparison of the descriptive epidemiology of urinary tract cancers. Cancer Causes Control. 1990 Sep;1(2):133–141. doi: 10.1007/BF00053164. [DOI] [PubMed] [Google Scholar]
  9. Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., DuBois R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994 Oct;107(4):1183–1188. doi: 10.1016/0016-5085(94)90246-1. [DOI] [PubMed] [Google Scholar]
  10. Emeigh Hart S. G., Beierschmitt W. P., Bartolone J. B., Wyand D. S., Khairallah E. A., Cohen S. D. Evidence against deacetylation and for cytochrome P450-mediated activation in acetaminophen-induced nephrotoxicity in the CD-1 mouse. Toxicol Appl Pharmacol. 1991 Jan;107(1):1–15. doi: 10.1016/0041-008x(91)90325-9. [DOI] [PubMed] [Google Scholar]
  11. Flaks A., Flaks B. Induction of liver cell tumours in IF mice by paracetamol. Carcinogenesis. 1983;4(4):363–368. doi: 10.1093/carcin/4.4.363-a. [DOI] [PubMed] [Google Scholar]
  12. Giovannucci E., Egan K. M., Hunter D. J., Stampfer M. J., Colditz G. A., Willett W. C., Speizer F. E. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995 Sep 7;333(10):609–614. doi: 10.1056/NEJM199509073331001. [DOI] [PubMed] [Google Scholar]
  13. Gobé G. C., Axelsen R. A. The role of apoptosis in the development of renal cortical tubular atrophy associated with healed experimental renal papillary necrosis. Pathology. 1991 Jul;23(3):213–223. doi: 10.3109/00313029109063569. [DOI] [PubMed] [Google Scholar]
  14. Henderson B. E., Ross R. K., Pike M. C. Toward the primary prevention of cancer. Science. 1991 Nov 22;254(5035):1131–1138. doi: 10.1126/science.1957166. [DOI] [PubMed] [Google Scholar]
  15. Jensen O. M., Knudsen J. B., Tomasson H., Sørensen B. L. The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. Int J Cancer. 1989 Dec 15;44(6):965–968. doi: 10.1002/ijc.2910440603. [DOI] [PubMed] [Google Scholar]
  16. Johansson S. L. Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int J Cancer. 1981;27(4):521–529. doi: 10.1002/ijc.2910270416. [DOI] [PubMed] [Google Scholar]
  17. Kari F., Bucher J., Haseman J., Eustis S., Huff J. Long-term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice. Jpn J Cancer Res. 1995 Mar;86(3):252–263. doi: 10.1111/j.1349-7006.1995.tb03048.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kokmen E., Beard C. M., O'Brien P. C., Offord K. P., Kurland L. T. Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960-1984) Neurology. 1993 Oct;43(10):1887–1892. doi: 10.1212/wnl.43.10.1887. [DOI] [PubMed] [Google Scholar]
  19. Kreiger N., Marrett L. D., Dodds L., Hilditch S., Darlington G. A. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993 Mar;4(2):101–110. doi: 10.1007/BF00053150. [DOI] [PubMed] [Google Scholar]
  20. Kyle M. E., Kocsis J. J. The effect of age on salicylate-induced nephrotoxicity in male rats. Toxicol Appl Pharmacol. 1985 Nov;81(2):337–347. doi: 10.1016/0041-008x(85)90171-1. [DOI] [PubMed] [Google Scholar]
  21. Mahony J. F., Storey B. G., Ibañez R. C., Stewart J. H. Analgesic abuse, renal parenchymal disease and carcinoma of the kidney or ureter. Aust N Z J Med. 1977 Oct;7(5):463–469. doi: 10.1111/j.1445-5994.1977.tb03366.x. [DOI] [PubMed] [Google Scholar]
  22. McCredie M., Ford J. M., Stewart J. H. Risk factors for cancer of the renal parenchyma. Int J Cancer. 1988 Jul 15;42(1):13–16. doi: 10.1002/ijc.2910420104. [DOI] [PubMed] [Google Scholar]
  23. McCredie M., Ford J. M., Taylor J. S., Stewart J. H. Analgesics and cancer of the renal pelvis in New South Wales. Cancer. 1982 Jun 15;49(12):2617–2625. doi: 10.1002/1097-0142(19820615)49:12<2617::aid-cncr2820491235>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  24. McCredie M., Pommer W., McLaughlin J. K., Stewart J. H., Lindblad P., Mandel J. S., Mellemgaard A., Schlehofer B., Niwa S. International renal-cell cancer study. II. Analgesics. Int J Cancer. 1995 Jan 27;60(3):345–349. doi: 10.1002/ijc.2910600312. [DOI] [PubMed] [Google Scholar]
  25. McCredie M., Stewart J. H., Day N. E. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer. 1993 Jan 21;53(2):245–249. doi: 10.1002/ijc.2910530212. [DOI] [PubMed] [Google Scholar]
  26. McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996 Aug;47(2):425–432. doi: 10.1212/wnl.47.2.425. [DOI] [PubMed] [Google Scholar]
  27. McLaughlin J. K., Blot W. J., Mehl E. S., Fraumeni J. F., Jr Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr. 1985 Dec;69:217–222. [PubMed] [Google Scholar]
  28. McMurtry R. J., Snodgrass W. R., Mitchell J. R. Renal necrosis, glutathione depletion, and covalent binding after acetaminophen. Toxicol Appl Pharmacol. 1978 Oct;46(1):87–100. doi: 10.1016/0041-008x(78)90139-4. [DOI] [PubMed] [Google Scholar]
  29. Mellemgaard A., Niwa S., Mehl E. S., Engholm G., McLaughlin J. K., Olsen J. H. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol. 1994 Oct;23(5):923–930. doi: 10.1093/ije/23.5.923. [DOI] [PubMed] [Google Scholar]
  30. Meyer J. S., Rogers R. L., McClintic K., Mortel K. F., Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989 Jun;37(6):549–555. doi: 10.1111/j.1532-5415.1989.tb05688.x. [DOI] [PubMed] [Google Scholar]
  31. Mitchell J. R., McMurtry R. J., Statham C. N., Nelson S. D. Molecular basis for several drug-induced nephropathies. Am J Med. 1977 Apr;62(4):518–526. doi: 10.1016/0002-9343(77)90407-7. [DOI] [PubMed] [Google Scholar]
  32. Nakanishi K., Kurata Y., Oshima M., Fukushima S., Ito N. Carcinogenicity of phenacetin: long-term feeding study in B6c3f1 mice. Int J Cancer. 1982 Apr 15;29(4):439–444. doi: 10.1002/ijc.2910290413. [DOI] [PubMed] [Google Scholar]
  33. Nanra R. S. Renal effects of antipyretic analgesics. Am J Med. 1983 Nov 14;75(5A):70–81. doi: 10.1016/0002-9343(83)90235-8. [DOI] [PubMed] [Google Scholar]
  34. Paganini-Hill A., Chao A., Ross R. K., Henderson B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989 Nov 18;299(6710):1247–1250. doi: 10.1136/bmj.299.6710.1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  36. Perneger T. V., Whelton P. K., Klag M. J. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994 Dec 22;331(25):1675–1679. doi: 10.1056/NEJM199412223312502. [DOI] [PubMed] [Google Scholar]
  37. Phenacetin and cancers of the urinary tract. N Engl J Med. 1985 Dec 5;313(23):1479–1480. doi: 10.1056/NEJM198512053132316. [DOI] [PubMed] [Google Scholar]
  38. Plummer D. T., Leathwood P. D., Blake M. E. Urinary enzymes and kidney damage by aspirin and phenacetin. Chem Biol Interact. 1975 Apr;10(4):277–284. doi: 10.1016/0009-2797(75)90092-7. [DOI] [PubMed] [Google Scholar]
  39. Pommer W., Bronder E., Greiser E., Helmert U., Jesdinsky H. J., Klimpel A., Borner K., Molzahn M. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol. 1989;9(5):403–412. doi: 10.1159/000168002. [DOI] [PubMed] [Google Scholar]
  40. Prescott L. F. Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs. 1982 Jan-Feb;23(1-2):75–149. doi: 10.2165/00003495-198223010-00004. [DOI] [PubMed] [Google Scholar]
  41. Rosenberg L., Rao R. S., Palmer J. R., Strom B. L., Zauber A., Warshauer M. E., Stolley P. D., Shapiro S. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control. 1998 Jan;9(1):83–88. doi: 10.1023/a:1008805505154. [DOI] [PubMed] [Google Scholar]
  42. Ruffin M. T., 4th, Krishnan K., Rock C. L., Normolle D., Vaerten M. A., Peters-Golden M., Crowell J., Kelloff G., Boland C. R., Brenner D. E. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst. 1997 Aug 6;89(15):1152–1160. doi: 10.1093/jnci/89.15.1152. [DOI] [PubMed] [Google Scholar]
  43. Sabatini S. Pathophysiologic mechanisms in analgesic-induced papillary necrosis. Am J Kidney Dis. 1996 Jul;28(1 Suppl 1):S34–S38. doi: 10.1016/s0272-6386(96)90567-3. [DOI] [PubMed] [Google Scholar]
  44. Sandler D. P., Burr F. R., Weinberg C. R. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991 Aug 1;115(3):165–172. doi: 10.7326/0003-4819-115-3-165. [DOI] [PubMed] [Google Scholar]
  45. Sandler D. P., Smith J. C., Weinberg C. R., Buckalew V. M., Jr, Dennis V. W., Blythe W. B., Burgess W. P. Analgesic use and chronic renal disease. N Engl J Med. 1989 May 11;320(19):1238–1243. doi: 10.1056/NEJM198905113201903. [DOI] [PubMed] [Google Scholar]
  46. Segasothy M., Samad S. A., Zulfigar A., Bennett W. M. Chronic renal disease and papillary necrosis associated with the long-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J Kidney Dis. 1994 Jul;24(1):17–24. doi: 10.1016/s0272-6386(12)80155-7. [DOI] [PubMed] [Google Scholar]
  47. Tsuda H., Sakata T., Masui T., Imaida K., Ito N. Modifying effects of butylated hydroxyanisole, ethoxyquin and acetaminophen on induction of neoplastic lesions in rat liver and kidney initiated by N-ethyl-N-hydroxyethylnitrosamine. Carcinogenesis. 1984 Apr;5(4):525–531. doi: 10.1093/carcin/5.4.525. [DOI] [PubMed] [Google Scholar]
  48. Yuan J. M., Castelao J. E., Gago-Dominguez M., Ross R. K., Yu M. C. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer. 1998 May;77(9):1508–1513. doi: 10.1038/bjc.1998.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yuan J. M., Castelao J. E., Gago-Dominguez M., Yu M. C., Ross R. K. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):429–433. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES